Sponsor-Investigators

Xiuning Le

HCRN-LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status

Open to Accrual

Cancer Types

Lung

Locations

Florida, MD Anderson Cancer Center, Moffitt Cancer Center, Texas